Rueda F - Search Results

1

Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity.

Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG. Cruz LJ, et al. Among authors: rueda f. Nanomedicine (Lond). 2017 Mar;12(5):491-510. doi: 10.2217/nnm-2016-0295. Epub 2017 Feb 9. Nanomedicine (Lond). 2017. PMID: 28181470

2

Targeting nanoparticles to dendritic cells for immunotherapy.

Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Cruz LJ, et al. Among authors: rueda f. Methods Enzymol. 2012;509:143-63. doi: 10.1016/B978-0-12-391858-1.00008-3. Methods Enzymol. 2012. PMID: 22568905 Review.

3

Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.

Cruz LJ, Rueda F, Tacken P, Albericio F, Torensma R, Figdor CG. Cruz LJ, et al. Among authors: rueda f. Nanomedicine (Lond). 2012 Oct;7(10):1591-610. doi: 10.2217/nnm.12.131. Nanomedicine (Lond). 2012. PMID: 23148541 Review.

4

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation.

Cruz LJ, Tacken PJ, van der Schoot JMS, Rueda F, Torensma R, Figdor CG. Cruz LJ, et al. Among authors: rueda f. Molecules. 2019 May 12;24(9):1825. doi: 10.3390/molecules24091825. Molecules. 2019. PMID: 31083610 Free PMC article.

5

Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.

Cruz LJ, Rueda F, Simón L, Cordobilla B, Albericio F, Domingo JC. Cruz LJ, et al. Among authors: rueda f. Nanomedicine (Lond). 2014 Apr;9(4):435-49. doi: 10.2217/NNM.13.66. Nanomedicine (Lond). 2014. PMID: 24910875

6

Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.

Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CW, Ossendorp F. Cruz LJ, et al. Among authors: rueda f. J Control Release. 2014 Oct 28;192:209-18. doi: 10.1016/j.jconrel.2014.07.040. Epub 2014 Jul 25. J Control Release. 2014. PMID: 25068703

7

Targeting the Brain with Nanomedicine.

Rueda F, Cruz LJ. Rueda F, et al. Curr Pharm Des. 2017;23(13):1879-1896. doi: 10.2174/1381612822666161221153228. Curr Pharm Des. 2017. PMID: 28003011 Review.

8

Effect of TLR ligands co-encapsulated with multiepitopic antigen in nanoliposomes targeted to human DCs via Fc receptor for cancer vaccines.

Rueda F, Eich C, Cordobilla B, Domingo P, Acosta G, Albericio F, Cruz LJ, Domingo JC. Rueda F, et al. Immunobiology. 2017 Nov;222(11):989-997. doi: 10.1016/j.imbio.2017.06.002. Epub 2017 Jun 10. Immunobiology. 2017. PMID: 28624137

9

Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy.

Cruz LJ, Rueda F, Cordobilla B, Simón L, Hosta L, Albericio F, Domingo JC. Cruz LJ, et al. Among authors: rueda f. Mol Pharm. 2011 Feb 7;8(1):104-16. doi: 10.1021/mp100178k. Epub 2010 Dec 20. Mol Pharm. 2011. PMID: 21121669

10

Combinatorial prospects of nano-targeted chemoimmunotherapy.

Da Silva CG, Rueda F, Löwik CW, Ossendorp F, Cruz LJ. Da Silva CG, et al. Among authors: rueda f. Biomaterials. 2016 Mar;83:308-20. doi: 10.1016/j.biomaterials.2016.01.006. Epub 2016 Jan 9. Biomaterials. 2016. PMID: 26796043 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page